Latest news newssearch boxGO All Ad hoc Other 28 Jul 2021 Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today 28 Jul 2021 Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company 28 Jul 2021 Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company 27 Jul 2021 Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company 28 Jun 2021 Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction 09 Jun 2021 Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021 25 May 2021 European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features 12 May 2021 Idorsia holds its Annual General Meeting of Shareholders 22 Apr 2021 Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway 01 Apr 2021 Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders 26 Mar 2021 The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis 19 Mar 2021 US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis 10 Mar 2021 FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia 03 Mar 2021 Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia 01 Mar 2021 Idorsia submits NDA for clazosentan to Japanese PMDA 04 Feb 2021 Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data 02 Feb 2021 Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal 11 Jan 2021 Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA 23 Nov 2020 Idorsia announces positive results of the two Japanese registration studies with clazosentan 27 Oct 2020 Idorsia announces financial results for the first nine months of 2020 1 2 3 4 5 6 7 8